Sekisui Diagnostics invests £14.4M in cGMP biopharma CDMO capacity expansion

Sekisui Diagnostics announced a £14.4 million investment to expand cGMP microbial fermentation and purification capacity at its Maidstone, Kent site, to be completed by the second half of 2022.

“This investment represents our commitment to serve our Biopharma customers with much needed cGMP microbial CDMO production capacity.”newswire.ca

• 1 source
• newswire.caSEKISUI Diagnostics Invests £14.4 Million in cGMP Biopharma CDMO CapacitySekisui DiagnosticsJul 29, 2020

Summarized from public sources; check the original articles before acting on it.